Loretta Sze-Mun Li

Title: Loretta Sze-Mun Li: Innovator in Janus Kinase Inhibitors

Introduction

Loretta Sze-Mun Li is a prominent inventor based in Chicago, IL (US). She has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that act as inhibitors for Janus kinase 2 (JAK2). Her innovative work has the potential to impact the treatment of various proliferative diseases.

Latest Patents

Loretta holds a patent for "Benzothiazole derivatives and 7-aza-benzothiazole derivatives as Janus kinase 2 inhibitors and uses thereof." This patent includes compounds of Formula (I), along with their pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs. The compounds are designed to inhibit Janus kinase 2, providing a new avenue for therapeutic applications.

Career Highlights

Loretta is affiliated with the Dana-Farber Cancer Institute Inc., where she continues her research and development efforts. Her work focuses on creating effective pharmaceutical compositions and kits that utilize her patented compounds.

Collaborations

Throughout her career, Loretta has collaborated with notable colleagues, including Nathanael S. Gray and Tinghu Zhang. These partnerships have enhanced her research and contributed to the advancement of her innovative projects.

Conclusion

Loretta Sze-Mun Li is a trailblazer in the field of pharmaceutical innovation, particularly in the development of JAK2 inhibitors. Her contributions are paving the way for new treatments in the medical field.